Direct-acting antiviral therapy reduces variceal rebleeding and improves liver function in hepatitis C virus-related cirrhosis: A multicenter retrospective cohort study

Table 17 Multivariate regression analyses adjusted for study center as a covariate (sensitivity analysis)

Outcome	Variable	Adjusted HR/OR (95%CI)	P value
Variceal Rebleeding (Cox)	SVR achieved	0.52 (0.34-0.81)	0.004
	MELD score ≥ 15	1.78 (1.12-2.84)	0.015
	History of EVL	0.67 (0.45-1.00)	0.049
	Study center (ref = C1)	HR range: 0.91-1.16	> 0.1
Hepatic Decompensation (Logistic)	SVR achieved	0.47 (0.25-0.90)	0.022
	Platelet count < 100 × 109/L	2.14 (1.10-4.17)	0.026
	Study Center (ref = C1)	OR range: 0.95-1.21	> 0.1
Mortality (Cox)	SVR achieved	0.58 (0.36-0.94)	0.028
	Child-Pugh C	2.30 (1.41-3.75)	0.001
	Study Center (ref = C1)	HR range: 0.88-1.19	> 0.1

C1-C5 refer to the five participating centers. No statistically significant differences were observed across centers in any model. MELD: Model for end-stage liver disease; SVR: Sustained virologic response; EVL: Endoscopic variceal ligation.